CRISPR Therapeutics and Vertex to Host Investor Webcast to Review Data Presented at the 62nd American Society of Hematology A...
December 01 2020 - 9:00AM
CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals
Incorporated (Nasdaq: VRTX) today announced that the companies will
host an investor webcast on December 9, 2020 at 8:00 a.m. ET to
review clinical data presented during the Plenary Scientific
Session at the annual ASH Meeting and Exposition from two ongoing
Phase 1/2 clinical trials of the investigational CRISPR/Cas9
gene-editing therapy CTX001 in patients with sickle cell disease
and beta thalassemia. The presentation will include speakers from
Vertex and CRISPR Therapeutics as well as Haydar Frangoul M.D.,
Medical Director of Pediatric Hematology and Oncology at Sarah
Cannon Research Institute, HCA Healthcare’s TriStar Centennial
Medical Center, and a principal investigator in the CTX001 clinical
studies.
The conference call will be webcast live and a
link to the webcast can be accessed on the CRISPR Therapeutics
website at https://crisprtx.gcs-web.com/events in the Investors
section under Events and Presentations and on the Vertex website at
www.vrtx.com in the "Investors" section. To access the call via
phone, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001
(International). To ensure a timely connection, it is recommended
that users register at least 15 minutes prior to the scheduled
webcast. An archived webcast will be available on the companies’
websites for approximately 30 days.
This meeting is not an official program of the
ASH annual meeting.
About the CRISPR-Vertex
CollaborationCRISPR Therapeutics and Vertex entered into a
strategic research collaboration in 2015 focused on the use of
CRISPR/Cas9 to discover and develop potential new treatments aimed
at the underlying genetic causes of human disease. CTX001
represents the first potential treatment to emerge from the joint
research program. CRISPR Therapeutics and Vertex will jointly
develop and commercialize CTX001 and equally share all research and
development costs and profits worldwide.
About CRISPR TherapeuticsCRISPR
Therapeutics is a leading gene editing company focused on
developing transformative gene-based medicines for serious diseases
using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a
revolutionary gene editing technology that allows for precise,
directed changes to genomic DNA. CRISPR Therapeutics has
established a portfolio of therapeutic programs across a broad
range of disease areas including hemoglobinopathies, oncology,
regenerative medicine and rare diseases. To accelerate and expand
its efforts, CRISPR Therapeutics has established strategic
collaborations with leading companies including Bayer, Vertex
Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is
headquartered in Zug, Switzerland, with its wholly-owned U.S.
subsidiary, CRISPR Therapeutics, Inc., and R&D operations based
in Cambridge, Massachusetts, and business offices in San Francisco,
California and London, United Kingdom. For more information, please
visit www.crisprtx.com.
CRISPR Therapeutics Forward-Looking
StatementThis press release may contain a number of
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended, including
statements regarding CRISPR Therapeutics’ expectations about plans
to review data presented at the annual ASH Meeting and Exposition
from two ongoing Phase 1/2 clinical trials of CTX001 in patients
with sickle cell disease and beta thalassemia, as well as the
anticipated speakers participating in the investor webcast.
Although CRISPR Therapeutics believes that such statements are
based on reasonable assumptions within the bounds of its knowledge
of its business and operations, existing and prospective investors
are cautioned that forward-looking statements are inherently
uncertain and not to place undue reliance on such statements, which
speak only as of the date they are made. Actual performance and
results may differ materially from those projected or suggested in
the forward-looking statements due to various risks and
uncertainties. These risks and uncertainties include, among others:
the potential that preliminary data from any clinical trial not to
be indicative of final trial results; the potential that clinical
trial results may not support registration or further development;
uncertainties regarding the intellectual property protection for
CRISPR Therapeutics’ technology; and those risks and uncertainties
described under the heading “Risk Factors” in CRISPR Therapeutics’
most recent annual report on Form 10-K, quarterly report on Form
10-Q, and in any other subsequent filings made by CRISPR
Therapeutics with the U.S. Securities and Exchange Commission,
which are available on the SEC's website at www.sec.gov. CRISPR
Therapeutics disclaims any obligation or undertaking to update or
revise any forward-looking statements contained in this press
release, other than to the extent required by law.
CRISPR THERAPEUTICS® word mark and design logo
and CTX001™ are trademarks and registered trademarks of CRISPR
Therapeutics AG. All other trademarks and registered trademarks are
the property of their respective owners.
About VertexVertex is a global
biotechnology company that invests in scientific innovation to
create transformative medicines for people with serious diseases.
The company has multiple approved medicines that treat the
underlying cause of cystic fibrosis (CF) — a rare, life-threatening
genetic disease — and has several ongoing clinical and research
programs in CF. Beyond CF, Vertex has a robust pipeline of
investigational small molecule medicines in other serious diseases
where it has deep insight into causal human biology, including
pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney
diseases. In addition, Vertex has a rapidly expanding pipeline of
genetic and cell therapies for diseases such as sickle cell
disease, beta thalassemia, Duchenne muscular dystrophy and type 1
diabetes mellitus.
Founded in 1989 in Cambridge, Mass., Vertex's
global headquarters is now located in Boston's Innovation District
and its international headquarters is in London. Additionally, the
company has research and development sites and commercial offices
in North America, Europe, Australia and Latin America. Vertex is
consistently recognized as one of the industry's top places to
work, including 11 consecutive years on Science magazine's Top
Employers list and a best place to work for LGBTQ equality by the
Human Rights Campaign. For company updates and to learn more about
Vertex's history of innovation, visit www.vrtx.com or follow us on
Facebook, Twitter, LinkedIn, YouTube and Instagram.
Vertex Special Note Regarding
Forward-Looking Statements This press release
contains forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995, including, without
limitation, statements regarding the expectations and plans to
review data presented at the annual ASH meeting and exposition from
two ongoing Phase 1/2 clinical trials of the investigational
CRISPR/Cas9 gene-editing therapy CTX001 in patients with sickle
cell disease and beta thalassemia, and the anticipated speakers
participating in the investor webcast. While Vertex believes the
forward-looking statements contained in this press release are
accurate, these forward-looking statements represent the company's
beliefs only as of the date of this press release and there are a
number of risks and uncertainties that could cause actual events or
results to differ materially from those expressed or implied by
such forward-looking statements. Those risks and uncertainties
include, among other things, the potential for data from a limited
number of patients may not to be indicative of final clinical trial
results, that data from the company's development programs,
including its programs with its collaborators, may not support
registration or further development of its compounds due to safety,
efficacy or other reasons, and other risks listed under “Risk
Factors” in Vertex's most recent annual report and subsequent
quarterly reports filed with the Securities and Exchange Commission
and available through the company's website at www.vrtx.com. You
should not place undue reliance on these statements or the
scientific data presented. Vertex disclaims any obligation to
update the information contained in this press release as new
information becomes available.
(VRTX-GEN)
CRISPR Therapeutics Investor
Contact:Susan Kim, +1
617-307-7503susan.kim@crisprtx.com
CRISPR Therapeutics Media
Contact:Rachel EidesWCG on behalf of CRISPR+1
617-337-4167reides@wcgworld.com
Vertex Pharmaceuticals
IncorporatedInvestors:Michael Partridge,
+1 617-341-6108orZach Barber, +1 617-341-6470orBrenda Eustace, +1
617-341-6187
Media:mediainfo@vrtx.com
orU.S.: +1 617-341-6992orHeather Nichols: +1
617-839-3607orInternational: +44 20 3204 5275
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Sep 2023 to Sep 2024